BCRX
Biocryst Pharmaceuticals Inc
NASDAQ · Biotechnology
$6.38
+0.14 (+2.24%)
Open$6.44
Previous Close$6.24
Day High$6.44
Day Low$6.26
52W High$11.31
52W Low$6.00
Volume—
Avg Volume4.30M
Market Cap1.58B
P/E Ratio—
EPS$-0.05
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+936.4% upside
Current
$6.38
$6.38
Target
$66.12
$66.12
$46.17
$66.12 avg
$78.89
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 540.87M | 380.74M | 351.53M |
| Net Income | -106,656,788 | -67,570,821 | -74,073,813 |
| Profit Margin | -19.7% | -18.7% | -21.1% |
| EBITDA | -1,562,645 | -1,044,989 | -81,791,824 |
| Free Cash Flow | — | — | -74,299,092 |
| Rev Growth | +42.1% | +42.1% | +19.3% |
| Debt/Equity | 2.09 | 2.09 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |